Comparative Pharmacology
Head-to-head clinical analysis: CEQUA versus MYFORTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEQUA versus MYFORTIC.
CEQUA vs MYFORTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunosuppressant; binds to cyclophilin D in mitochondria, inhibiting opening of mitochondrial permeability transition pore (mPTP), which reduces T-lymphocyte activation and cytokine release. Also forms complex with cyclophilin A to inhibit calcineurin, suppressing IL-2 production and T-cell proliferation.
Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), thereby depleting guanosine nucleotides in T and B lymphocytes, suppressing their proliferation and antibody production.
Instill one drop of 0.09% ophthalmic solution in each eye twice daily, approximately 12 hours apart.
720 mg orally twice daily, on an empty stomach, 1 hour before or 2 hours after meals.
None Documented
None Documented
Terminal elimination half-life is approximately 8.4 hours (range 6-10 hours) in healthy adults; prolonged in hepatic impairment and pediatric patients.
Terminal elimination half-life is approximately 12-18 hours (mean 17 hours) in healthy volunteers; longer in hepatic impairment (up to 40 hours).
Primarily fecal (90%) with minor renal excretion (<1% unchanged drug). Biliary excretion is the major route for elimination of cyclosporine metabolites.
Primarily renal (approximately 95% as metabolites, <3% as unchanged drug); biliary/fecal excretion accounts for <5%.
Category C
Category C
Immunosuppressant
Immunosuppressant